FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive Keytruda. The U.S. Food and Drug Administration (FDA) has approved PD ...
Clinical trials have proven the power of immunotherapies targeting PD-L1 or PD-1 in a range of cancers. However, these same trials show that only some patients benefit - tumors must depend on PD-L1 to ...
FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda. Agilent Technologies Inc. announced that the U.S. Food and ...
MADISON, N.J., Oct. 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it now provides clinical laboratory ...
BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH) a leading global life sciences company, today announced the U.S. availability of the PD-L1 IHC 28-8 pharmDx assay as a complementary diagnostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results